A Problematic Biomarker Trial Design

Boris Freidlin

doi:10.1093/jnci/djab144

2021-07-21

Boris Freidlin *

Edward L. Korn

DOI：10.1093/jnci/djab144

原文链接

原文求助

摘要

En 中文

Efficient biomarker-driven randomized clinical trials are a key tool for implementing precision oncology. A commonly used biomarker phase III design is focused on testing the treatment effect in biomarker-positive and overall study populations. This approach may result in recommending new treatments to biomarker-negative patients when these treatments have no benefit for these patients.

期刊

JNCI-Journal of the National Cancer Institute

IF:

7.2

论文数:

6.2K

被引数:

3.3W

机构

national institutes of health (nih) - usa

学者数:

10.3W

论文数: 8.2W

被引数: 111

引用论文

Atezolizumab for PD-L1-Selected Patients with NSCLC

NEW ENGLAND JOURNAL OF MEDICINE

IF78.5

2021-02-11

PREAI

Horita, Nobuyuki; Fukuda, Nobuhiko; Kaneko, Takeshi

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer 阿特珠单抗和Nab-紫杉醇治疗晚期三阴性乳腺癌

NEW ENGLAND JOURNAL OF MEDICINE

IF78.5

2018-11-29

3.2K

OAAI

Schmid, P.; Adams, S.; Rugo, H. S.; Schneeweiss, A.; Barrios, C. H.; Iwata, H.; Dieras, V.; Hegg, R.; Im, S. -A.; Wright, G. Shaw; Henschel, V.; Molinero, L.; Chui, S. Y.; Funke, R.; Husain, A.; Winer, E. P.; Loi, S.; Emens, L. A.

A survey of galaxy redshifts. IV - The data

The Astrophysical Journal Supplement Series

IF0

1983-06-01

OAAI

J. Huchra; M. Davis; D. Latham; J. Tonry

IEEE Standard for Local and metropolitan area networks: Media Access Control (MAC) Bridges

IF0

2022-04-01

PREAI

PD-L1 as a biomarker of response to immune-checkpoint inhibitors PD-L1作为免疫检查点抑制剂反应的生物标志物

NATURE REVIEWS CLINICAL ONCOLOGY

IF82.2

2021-02-12

844

PREAI

Doroshow, Deborah Blythe; Bhalla, Sheena; Beasley, Mary Beth; Sholl, Lynette M.; Kerr, Keith M.; Gnjatic, Sacha; Wistuba, Ignacio I.; Rimm, David L.; Tsao, Ming Sound; Hirsch, Fred R.

BAGS: A Bayesian Adaptive Group Sequential Trial Design With Subgroup-Specific Survival Comparisons

JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION

IF3

2020-11-30

OAAI

Lin, Ruitao; Thall, Peter F.; Yuan, Ying

Pembrolizumab for all PD-L1-positive NSCLC

LANCET

IF88.5

2019-05-01

PREAI

Smit, Egbert F.; de langen, Adrianus J.

Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC

NEW ENGLAND JOURNAL OF MEDICINE

IF78.5

2020-10-01

1.1K

OAAI

Herbst, Roy S.; Giaccone, Giuseppe; de Marinis, Filippo; Reinmuth, Niels; Vergnenegre, Alain; Barrios, Carlos H.; Morise, Masahiro; Felip, Enriqueta; Andric, Zoran; Geater, Sarayut; Ozguroglu, Mustafa; Zou, Wei; Sandler, Alan; Enquist, Ida; Komatsubara, Kimberly; Deng, Yu; Kuriki, Hiroshi; Wen, Xiaohui; McCleland, Mark; Mocci, Simonetta; Jassem, Jacek; Spigel, David R.

Biomarker enrichment strategies: matching trial design to biomarker credentials

NATURE REVIEWS CLINICAL ONCOLOGY

IF82.2

2013-11-26

140

PREAI

Freidlin, Boris; Korn, Edward L.

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial Pembrolizumab与化疗治疗未经治疗的PD-L1-expressing、局部晚期或转移性非小细胞肺癌 (KEYNOTE-042): 一项随机、开放标签、对照、3期临床试验

LANCET

IF88.5

2019-05-01

2.5K

PREAI

Mok, Tony S. K.; Wu, Yi-Long; Kudaba, Iveta; Kowalski, Dariusz M.; Cho, Byoung Chul; Turna, Hande Z.; Castro, Gilberto, Jr.; Srimuninnimit, Vichien; Laktionov, Konstantin K.; Bondarenko, Igor; Kubota, Kaoru; Lubiniecki, Gregory M.; Zhang, Jin; Kush, Debra; Lopes, Gilberto

查看更多内容